U

United Therapeutics Corporation

Biotech company develops PAH therapies

GMP Maintenance Technician 2 / Senior GMP Maintenance Technician

Full-TimeUpdated on 10/17/2026
No salary listed
Mid, Senior
Associate's
Durham, NC, USA
In Person100% on-site at the Durham office.
General Maintenance & RepairEquipment Maintenance

About the job

Requirements
  • A high school diploma or General Education Degree (GED) is required.
  • For GMP Maintenance Technician II level, a minimum of 4 years of experience as maintenance personnel in an industrial, pharmaceutical/biotechnology, or manufacturing environment is required.
  • For Senior GMP Maintenance Technician level, a minimum of 6 years of experience as maintenance personnel in an industrial, pharmaceutical/biotechnology, or manufacturing environment is required.
  • Proficiency in all Microsoft Office applications is required.
  • Experience troubleshooting and repairing pneumatic, electronic, and hydraulic control systems, including diagnosing non-routine issues, is required.
  • Working knowledge of test equipment such as digital voltmeters, temperature probes, and pneumatic calibrators is required.
  • Strong organizational and problem-solving skills are required.
  • Written and verbal communication skills sufficient to communicate effectively across functions and with external vendors are required.
  • The ability to provide guidance or technical support to less experienced technicians is required.
Responsibilities
  • Execute planned and unplanned routine maintenance and repairs on manufacturing, filling, assembly, and packing/kitting lines to ensure efficient production and supply of Tyvaso DPI medicine.
  • Work closely with Mechanics team members to complete maintenance events on time, document events in a Computerized Maintenance Management System (CMMS), and maintain an accurate spare parts inventory.
  • Assist with equipment operations and work with stakeholders and vendors to anticipate and resolve mechanical and automated equipment issues while adhering to current Good Manufacturing Practices (cGMPs).
  • Understand the role equipment and systems play in meeting Critical Process Parameters (CPPs), certificate of pharmaceutical product requirements, and other regulatory guidelines in DPI manufacturing and kitting operations.
  • Perform preventative maintenance on equipment and update BMRAM to maintain accurate records with limited supervision.
  • Troubleshoot and diagnose mechanical, electrical, and operational issues on production equipment, using technical judgment to resolve non-routine issues and ensure problems are addressed promptly and effectively.
  • Maintain proficiency in GMP maintenance responsibilities and apply working knowledge to improve equipment performance and reliability.
  • Assist with obtaining maintenance proposals, approving purchase orders, and procuring spare parts inventory from external vendors to support DPI manufacturing and kitting equipment.
  • Coordinate with external vendors during site visits to perform maintenance activities on production equipment.
  • Support quality events, deviations, change controls, CAPAs, and action items in TrackWise related to DPI manufacturing and kitting, including investigations and follow-up actions.
  • Support completion of validations, special projects, audits, and other requirements, contributing to execution and documentation; this may include travel to other United Therapeutics or vendor sites.
  • Perform other duties as assigned.
Desired Qualifications
  • An associate degree in life science, mechanical studies, or technical vocational studies in a related field is preferred.
  • Experience with automation systems and platforms is preferred.
  • Advanced ability to troubleshoot and operate complex automation systems and resolve non-routine issues is preferred.
  • Experience using a regulated database such as BMRAM or Cal Man is preferred.
  • Four or more years of experience in the pharmaceutical or medical devices industry is preferred.

About the company

U

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Silver Spring, Maryland

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted ralinepag NDA August 2026 and nebulized Tyvaso sNDA September 2026.
  • Q2 2026 net income rose to $333 million; buybacks retired 5.84% shares.
  • Phase 3 ADVANCE OUTCOMES and TETON showed improvement across PAH and IPF programs.

What critics are saying

  • Q2 2026 revenue fell 2%; Tyvaso sales dropped, exposing heavy product concentration.
  • Liquidia’s appeals and labeling fights can still blunt Treprostinil economics by 2027.
  • If ralinepag and IPF filings disappoint FDA, United Therapeutics remains a single-portfolio biotech.

What makes United Therapeutics Corporation unique

  • Martine Rothblatt built United Therapeutics around PAH drugs plus xenotransplantation, with three operating organ sites.
  • September 2026 Delaware ruling strengthened its treprostinil patent moat against Liquidia’s Yutrepia.
  • Stewartville’s August 12, 2026 DPF facility expands gene-edited pig organ production capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Holidays
  • Paid Vacation
  • Parental Leave

Company News

Associated Press
Oct 20th, 2026
United Therapeutics opens third pathogen-free xenograft facility in Houston to scale organ production

United Therapeutics has opened its third Designated Pathogen-Free (DPF) facility, in Houston, Texas. The site produces xenografts, which are animal organs for transplant into humans. The first facility opened in Christiansburg, Virginia, in 2024 to supply clinical trials. The second opened in Stewartville, Minnesota, on August 12, 2026. The Houston and Stewartville sites are built to scale commercial production if regulators approve the products. The facilities use air and water filtration, filtered feed, and decontamination entryways to keep out pathogens. Solar arrays offset a significant part of their energy use. "Every day, people with end-stage organ disease die waiting for an organ that never comes," said chief executive officer Martine Rothblatt. The products remain investigational and are not approved anywhere.

The Business Journals
Oct 20th, 2026
United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth.

United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth. Oct 20, 2026 Preview this article 1 min United Therapeutics has been working toward a Houston presence for over a year, and its newly opened facility will soon call pharma giants Eli Lilly and Bristol Myers Squibb its neighbors. Don't Stop Here - Continue Reading For $1 Per Week Secure 4 weeks of award-winning news and trusted insights Subscribe for only $4

Yahoo Finance
Oct 16th, 2026
Two cash-rich stocks to watch, United Therapeutics and Core Natural Resources, and one to avoid

StockStory has named two cash-generating stocks to watch and one to avoid, arguing that strong cash flow alone does not guarantee good returns. It passes on Simply Good Foods, the maker of Atkins products. Revenue grew 5.2% annually over three years, sales are estimated to fall 9.9% in the next 12 months, and operating margin dropped 31.9 percentage points. The stock trades at $11.12, or 6.5x forward earnings. United Therapeutics, with a free cash flow margin of 34.6%, grew revenue 14.7% a year over five years and posts a 29.1% return on capital. It trades at $541.55, or 18.3x forward earnings. Core Natural Resources, a coal miner with a 6.1% free cash flow margin, grew revenue 15.6% annually over ten years to $4.27 billion. Its shares cost $89.05, or 20.7x forward earnings.

STAT
Oct 14th, 2026
FDA adcomm members' ties to industry under scrutiny.

FDA adcomm members' ties to industry under scrutiny. The FTC going after Martin Shkreli again, a study on GLP-1s and social outcomes, and more biotech news. Oct. 14, 2026 National Biotech Reporter Good morning. Yesterday, we got the devastating news that STAT's infectious disease correspondent, Helen Branswell, passed away. She was a reporter I always looked up to and was also an incredibly generous colleague. Please take the time to read this tribute to her. The need-to-know this morning. * Liquidia and United Therapeutics reached a settlement agreement that resolves their ongoing patent litigation over Liquidia's treatment for pulmonary arterial hypertension. New trial to test effect of GLP-1s on social outcomes. Researchers in Pittsburgh are launching a novel type of GLP-1 trial - testing not only if the drug will help people with addiction, but also if it will help reduce recidivism while improving other employment, health, and housing outcomes. The Center for Addiction Science, Policy and Research (CASPR), a non-profit organizing the effort, and the Allegheny County Department of Human Services are planning to launch the trial in early 2027. They will enroll up to 1,200 adults with alcohol use disorder, opioid use disorder, or both, who are also at high risk of criminal-justice involvement. Half will be randomly assigned to take Novo Nordisk's Wegovy, according to a press release issued yesterday. Your morning rundown of the science, politics, and money driving biotech today

Associated Press
Oct 13th, 2026
Liquidia to pay $380.7M to end all six lawsuits with United Therapeutics

Liquidia has settled all six lawsuits with United Therapeutics, ensuring patients with pulmonary arterial hypertension can keep using its inhaled drug YUTREPIA. The company will pay a net $380.7 million across 2026 and 2027. The deal follows a September 30, 2026, US District Court ruling that Liquidia infringed a United Therapeutics patent covering treatment of a related lung condition. Liquidia will not appeal and has asked to remove that indication from YUTREPIA's label. Payments include $175 million within 30 business days and $145.4 million in two instalments of $72.7 million, due by January 31, 2027, and April 30, 2027. Liquidia will also pay $60.3 million this month to parties with interests in related antitrust litigation. Liquidia reported preliminary third-quarter YUTREPIA net sales of $222.7 million and $396.1 million in cash as of September 30, 2026. It expects to fund the payments without new financing.